High resolution HLA genotyping with third generation sequencing technology-A multicentre study
- PMID: 39132735
- DOI: 10.1111/tan.15632
High resolution HLA genotyping with third generation sequencing technology-A multicentre study
Abstract
Molecular HLA typing techniques are currently undergoing a rapid evolution. While real-time PCR is established as the standard method in tissue typing laboratories regarding allocation of solid organs, next generation sequencing (NGS) for high-resolution HLA typing is becoming indispensable but is not yet suitable for deceased donors. By contrast, high-resolution typing is essential for stem cell transplantation and is increasingly required for questions relating to various disease associations. In this multicentre clinical study, the TGS technique using nanopore sequencing is investigated applying NanoTYPE™ kit and NanoTYPER™ software (Omixon Biocomputing Ltd., Budapest, Hungary) regarding the concordance of the results with NGS and its practicability in diagnostic laboratories. The results of 381 samples show a concordance of 99.58% for 11 HLA loci, HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1 and -DPB1. The quality control (QC) data shows a very high quality of the sequencing performed in each laboratory, 34,926 (97.15%) QC values were returned as 'passed', 862 (2.4%) as 'inspect' and 162 (0.45%) as 'failed'. We show that an 'inspect' or 'failed' QC warning does not automatically lead to incorrect HLA typing. The advantages of nanopore sequencing are speed, flexibility, reusability of the flow cells and easy implementation in the laboratory. There are challenges, such as exon coverage and the handling of large amounts of data. Finally, nanopore sequencing presents potential for applications in basic research within the field of epigenetics and genomics and holds significance for clinical concerns.
Keywords: HLA‐typing; NanoTYPE; deceased donor typing; donor specific antibody determination; high‐resolution typing; nanopore sequencing; single sample HLA‐typing; third generation sequencing.
© 2024 The Author(s). HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000;343:702‐709. doi:10.1056/NEJM200009073431006
-
- Chung W‐H, Hung S‐I, Hong H‐S, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004;428:486. doi:10.1038/428486a
-
- Daly AK, Donaldson PT, Bhatnagar P, et al. HLA‐B*5701 genotype is a major determinant of drug‐induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816‐819. doi:10.1038/ng.379
-
- Hung S‐I, Chung W‐H, Liou L‐B, et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134‐4139. doi:10.1073/pnas.0409500102
-
- Mosaad YM. Clinical role of human leukocyte antigen in health and disease. Scand J Immunol. 2015;82:283‐306. doi:10.1111/sji.12329
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
